|Mr. James A. Joyce Ph.D.||Founder, Chairman and Chief Exec. Officer||645.42k||N/A||55|
|Mr. Rodney S. Kenley||Pres and Director||318.75k||N/A||67|
|Mr. James B. Frakes||Chief Financial Officer||351.43k||N/A||60|
|Mr. Sunil Sawhney||Head of Clinical Studies||N/A||N/A||N/A|
|Dr. Kenneth R. Michael PharM.D., R.A.C.||Regulatory and Clinical Advisor||N/A||N/A||N/A|
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in cancer, infectious diseases, and other life-threatening conditions in the United States. The company develops Aethlon Hemopurifier, a medical device, which targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Its Aethlon Hemopurifier addresses antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. The company is also involved in developing exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. Aethlon Medical, Inc. was founded in 1991 and is based in San Diego, California.
Aethlon Medical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.